Radiogenomic signatures of oncotype DX recurrence score enable prediction of survival in estrogen receptor–positive breast cancer: A multicohort study
M Fan, Y Cui, C You, L Liu, Y Gu, W Peng, Q Bai… - Radiology, 2022 - pubs.rsna.org
Background Radiogenomics explores the association between imaging features and
genomic assays to uncover relevant prognostic features; however, the prognostic …
genomic assays to uncover relevant prognostic features; however, the prognostic …
Selecting postoperative adjuvant systemic therapy for early‐stage breast cancer: An updated assessment and systematic review of leading commercially available …
DM Hyams, A Bareket‐Samish… - Journal of Surgical …, 2024 - Wiley Online Library
Gene expression assays (GEAs) can guide treatment for early‐stage breast cancer. Several
large prospective randomized clinical trials, and numerous additional studies, now provide …
large prospective randomized clinical trials, and numerous additional studies, now provide …
Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter …
Background The Oncotype Dx recurrence score (ODx-RS) guides the adjuvant
chemotherapy decision-making process for patients with early-stage hormone receptor …
chemotherapy decision-making process for patients with early-stage hormone receptor …
MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification
Background The minichromosome maintenance protein-2 (MCM-2) is a more sensitive
proliferation marker than Ki-67. This study aimed to evaluate the relationship between MCM …
proliferation marker than Ki-67. This study aimed to evaluate the relationship between MCM …
Survival benefit of chemotherapy according to 21-gene recurrence score in young women with breast cancer
Abstract Background Initial trials evaluating Oncotype DX, reported as a recurrence score
(RS) from 0 to 100, were not powered to evaluate overall survival, and premenopausal …
(RS) from 0 to 100, were not powered to evaluate overall survival, and premenopausal …
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21‑gene recurrence score of 26‑30
J Yu, J Wu, O Huang, J He, L Zhu… - Oncology …, 2020 - spandidos-publications.com
Recurrence score (RS) could be used to predict clinical outcomes and chemotherapy
efficacy in patients with hormone receptor (HR)‑positive, human epidermal growth factor …
efficacy in patients with hormone receptor (HR)‑positive, human epidermal growth factor …
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study
O Rotem, I Peretz, M Leviov, I Kuchuk, A Itay… - NPJ Breast …, 2023 - nature.com
Data on adjuvant chemotherapy (CT) benefit in ER+ HER2‒early-stage breast cancer (EBC)
patients with Recurrence Score (RS) 26-30 are limited. This real-world study evaluated the …
patients with Recurrence Score (RS) 26-30 are limited. This real-world study evaluated the …
OPEN ACCESS EDITED BY
II Skvortsova, IM Talaat, M Zeinalian… - The tumor and …, 2024 - books.google.com
Background: The Oncotype Dx recurrence score (ODx-RS) guides the adjuvant
chemotherapy decision-making process for patients with early-stage hormone receptor …
chemotherapy decision-making process for patients with early-stage hormone receptor …
Personalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence–a systematic review and meta-analysis
SM Wallerstedt, A Nilsson Ek… - European Journal of …, 2020 - Springer
Purpose To assess the evidence for decision making, at the health care and the patient
levels, regarding the use of gene expression assays to inform chemotherapy decisions in …
levels, regarding the use of gene expression assays to inform chemotherapy decisions in …
Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26–30 and≥ 31
NF Berger, BS Zimmerman, S Tharakan, K Suchman… - Oncology, 2021 - karger.com
Background: The Oncotype DX Recurrence Score (ODx RS) is the most widely adopted
genomic assay used to guide treatment for patients with early-stage, hormone-positive …
genomic assay used to guide treatment for patients with early-stage, hormone-positive …